---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-24-000109"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:10:16.981400+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%

## Summary
- XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.
- Gross-to-net discount improved to 44% from 55% in Q1; steady state expected low 40% in 2025.
- More than 37,000 bottles delivered to patients in Q2; ~11,000 ECPs have started patients launch-to-date.
- Net loss $33.3M (($0.88) per share) vs $31.4M in Q2 2023; SG&A $58.8M vs $20.3M due to launch costs.
- Cash $323.6M including ~$39.6M from new credit facility draw; sales force expansion to ~50 additional reps by end of Q3.

## SEC filing metadata
- accession: 0001819790-24-000109
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000109/0001819790-24-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000109/tars-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-24-000109
- JSON: https://secwatch.observer/filing/0001819790-24-000109.json
- Plain text: https://secwatch.observer/filing/0001819790-24-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.